Kosdaq-listed company Adbiotech is hitting the upper price limit.
As of 9:12 AM on the 25th, Adbiotech was trading at 4,280 KRW on the Kosdaq market, up 985 KRW (29.89%) from the previous trading day.
Founded in 2000, Adbiotech primarily operates in the manufacturing of veterinary pharmaceuticals. It was selected as a promising small and medium enterprise in Gangwon Province in 2008 and received the Technology Innovation Award from the Ministry of Knowledge Economy in October of the same year.
The company is developing Helicobacter lgY, Cholesterol lgY, and natural medicine treatments for ulcerative colitis, aiming for individual certification of health functional foods in the human product market.
It was transferred to the Kosdaq market on January 24, 2022.
Choi Jae-ho, a researcher at Hana Securities, stated, "Attention should be paid to Adbiotech's new growth engine, which is the 'microbial agent' for food waste treatment," adding, "The domestic food waste treatment device market size was approximately 980 billion KRW as of last year, with a penetration rate of only about 5%, indicating ample room for growth."
Researcher Choi continued, "Within the rapidly growing food waste treatment device market, the microbial fermentation method should be noted. Starting this year, Adbiotech is expected to exclusively supply microbial agents for food waste treatment to the world's number one global home appliance company and a leading domestic rental company," and added, "Currently, small and medium enterprises hold the number one market share in microbial food waste treatment devices, but with the entry of large corporations into the rental service and built-in device markets, a shift in the market landscape is anticipated." He further stated, "Accordingly, Adbiotech, which exclusively supplies microbial agents, is expected to experience a steep growth in performance."
© The Asia Business Daily(www.asiae.co.kr). All rights reserved.
